- Home
- CRGX vs TRUE Comparison
CRGX vs TRUE Comparison
Compare CRGX & TRUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- TRUE
- Stock Information
- Founded
- CRGX 2021
- TRUE 2005
- Country
- CRGX United States
- TRUE United States
- Employees
- CRGX N/A
- TRUE N/A
- Industry
- CRGX
- TRUE Computer Software: Programming Data Processing
- Sector
- CRGX
- TRUE Technology
- Exchange
- CRGX Nasdaq
- TRUE Nasdaq
- Market Cap
- CRGX 207.5M
- TRUE 171.0M
- IPO Year
- CRGX 2023
- TRUE 2014
- Fundamental
- Price
- CRGX $4.54
- TRUE $1.87
- Analyst Decision
- CRGX Hold
- TRUE Buy
- Analyst Count
- CRGX 7
- TRUE 5
- Target Price
- CRGX $5.33
- TRUE $3.19
- AVG Volume (30 Days)
- CRGX 1.7M
- TRUE 487.6K
- Earning Date
- CRGX 08-06-2025
- TRUE 08-06-2025
- Dividend Yield
- CRGX N/A
- TRUE N/A
- EPS Growth
- CRGX N/A
- TRUE N/A
- EPS
- CRGX N/A
- TRUE N/A
- Revenue
- CRGX N/A
- TRUE $184,559,000.00
- Revenue This Year
- CRGX N/A
- TRUE $7.54
- Revenue Next Year
- CRGX N/A
- TRUE $11.02
- P/E Ratio
- CRGX N/A
- TRUE N/A
- Revenue Growth
- CRGX N/A
- TRUE 11.66
- 52 Week Low
- CRGX $3.00
- TRUE $1.05
- 52 Week High
- CRGX $25.45
- TRUE $4.62
- Technical
- Relative Strength Index (RSI)
- CRGX 59.56
- TRUE 49.27
- Support Level
- CRGX $4.45
- TRUE $1.88
- Resistance Level
- CRGX $4.51
- TRUE $2.29
- Average True Range (ATR)
- CRGX 0.04
- TRUE 0.18
- MACD
- CRGX -0.00
- TRUE -0.01
- Stochastic Oscillator
- CRGX 76.00
- TRUE 45.03
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.
About TRUE TrueCar Inc.
TrueCar Inc is a data-driven online platform operating on common technology infrastructure, powered by proprietary data and analytics. It also customizes and operates its platform for affinity group marketing partners, including financial institutions like PenFed and American Express; membership-based organizations like Consumer Reports, AARP, Sam's Club, and AAA; and employee buying programs for large enterprises such as IBM and Walmart. The Company has one operating segment, with three distinct service offerings: Dealer products and services, OEM incentives, and other.